Open AccessIn vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera
Author(s) -
Sacha J. Pidot,
Jessica L. Porter,
Troy Lister,
Timothy P. Stinear
Publication year - 2021
Publication title -
plos neglected tropical diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.99
H-Index - 135
eISSN - 1935-2735
pISSN - 1935-2727
DOI - 10.1371/journal.pntd.0009636
Subject(s) - mycobacterium marinum , mycobacterium ulcerans , antimycobacterial , mycobacterium , clarithromycin , nontuberculous mycobacteria , microbiology and biotechnology , rifampicin , biology , antibiotics , buruli ulcer , mycobacterium avium complex , virology , mycobacterium tuberculosis , medicine , tuberculosis , bacteria , pathology , disease , genetics
Nontuberculosis mycobacterial (NTM) infections are increasing in prevalence across the world. In many cases, treatment options for these infections are limited. However, there has been progress in recent years in the development of new antimycobacterial drugs. Here, we investigate the in vitro activity of SPR719, a novel aminobenzimidazole antibiotic and the active form of the clinical-stage compound, SPR720, against several isolates of Mycobacterium ulcerans , Mycobacterium marinum and Mycobacterium chimaera . We show that SPR719 is active against these NTM species with a MIC range of 0.125–4 μg/ml and that this compares favorably with the commonly utilized antimycobacterial antibiotics, rifampicin and clarithromycin. Our findings suggest that SPR720 should be further evaluated for the treatment of NTM infections.